

Product datasheet for **TL320324V**

DNMT3B Human shRNA Lentiviral Particle (Locus ID 1789)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	DNMT3B Human shRNA Lentiviral Particle (Locus ID 1789)
Locus ID:	1789
Synonyms:	ICF; ICF1; M.HsaIIIB
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	DNMT3B - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_001207055 , NM_001207056 , NM_006892 , NM_175848 , NM_175849 , NM_175850 , NM_175848.1 , NM_175850.1 , NM_175850.2 , NM_006892.1 , NM_006892.2 , NM_006892.3 , NM_175849.1 , NM_001207056.1 , NM_001207055.1 , BC111933 , BC118502 , NM_006892.4 , NM_001207055.2 , NM_001207056.2 , NM_175848.2 , NM_175849.2
UniProt ID:	Q9UBC3
Summary:	CpG methylation is an epigenetic modification that is important for embryonic development, imprinting, and X-chromosome inactivation. Studies in mice have demonstrated that DNA methylation is required for mammalian development. This gene encodes a DNA methyltransferase which is thought to function in de novo methylation, rather than maintenance methylation. The protein localizes primarily to the nucleus and its expression is developmentally regulated. Mutations in this gene cause the immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome. Eight alternatively spliced transcript variants have been described. The full length sequences of variants 4 and 5 have not been determined. [provided by RefSeq, May 2011]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).